Recent Trends in GI - Lung Cancers- Welcome & Introduction
Immune checkpoint Inhibitors in 1L Gastric Cancer GEJC and EAC
PD-1 blockade as curative-intent therapy in mismatch repair deficient locally advanced rectal cancer
Welcome & Introducation
Adjuvant Radiotherapy in Breast Cancer
MBC-To Operate the Primary or Not
Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC
Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC
NSCLC is a heterogeneous set of diseases defined by oncogenic drivers
Oncology Update - Welcome & Introduction
Uncommon Mutations in mNSCLC is it correct to rely on TKY
Neoadjuvant IO in Early Lung Cancer
Welcome & Introduction
Immunotherapy biomarkers in NSCLC
PD-L1 IHC testing landscape in NSCLC